Michael Lauseker, Markus Pfirrmann, Verena S. Hoffmann, Joerg Hasford. Comment on “Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed” Haematologica 2011;96(12):1779–82. Haematologica 2012;97(5):e14-e15; https://doi.org/10.3324/haematol.2011.061630.